<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id><journal-id journal-id-type="publisher-id">JVMS</journal-id><journal-title-group><journal-title>The Journal of Veterinary Medical Science</journal-title></journal-title-group><issn pub-type="ppub">0916-7250</issn><issn pub-type="epub">1347-7439</issn><publisher><publisher-name>The Japanese Society of Veterinary Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26972332</article-id><article-id pub-id-type="pmc">4976264</article-id><article-id pub-id-type="publisher-id">14-0673</article-id><article-id pub-id-type="doi">10.1292/jvms.14-0673</article-id><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject><subj-group><subject>Full Paper</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparison of the effects of long-term pimobendan and benazepril
administration in normal cats</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>MIYAGAWA</surname><given-names>Yuichi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>MACHIDA</surname><given-names>Noboru</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>TODA</surname><given-names>Noriko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>TOMINAGA</surname><given-names>Yoshinori</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>TAKEMURA</surname><given-names>Naoyuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1)</label>Division of Therapeutic Sciences I, Department of Veterinary
Clinical Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon
Veterinary and Life Science University, 1&#x02013;7&#x02013;1 Kyonan Cho, Musashino City, Tokyo 180&#x02013;8602,
Japan</aff><aff id="aff2"><label>2)</label>Department of Veterinary Clinical Oncology, Tokyo University
of Agriculture and Technology, 3&#x02013;5&#x02013;8 Saiwai-cho, Fuchu, Tokyo 183&#x02013;8509, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Miyagawa, Y., Laboratory of Veterinary
Integrative Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon
Veterinary and Life Science University, 1&#x02013;7&#x02013;1 Kyonan Cho, Musashino City, Tokyo 180&#x02013;8602,
Japan. e-mail: <email xlink:href="ymiyagawa@nvlu.ac.jp">ymiyagawa@nvlu.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><volume>78</volume><issue>7</issue><fpage>1099</fpage><lpage>1106</lpage><history><date date-type="received"><day>18</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9;2016 The Japanese Society of Veterinary Science</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>Pimobendan (PIMO) can cause adverse effects, such as mitral valve degeneration, in dogs;
however, it is unclear whether these effects occur in cats. Therefore, we aimed to
determine whether PIMO or benazepril produces adverse cardiac effects in healthy cats.
This was a blinded, randomized, prospective parallel study. Twelve cats were randomly
divided into two groups of six cats, namely, an angiotensin-converting-enzyme inhibitor
group that received benazepril and a PIMO group. Cats were administered their respective
treatments for 506 days, and we evaluated cardiac parameters, blood biochemistry and
glomerular filtration rates during that time. At the end of the trial, the cats were
euthanized, and histopathological examinations were performed by a pathologist who was
blinded to the treatment groups. No significant changes were observed in any of the
parameters measured in either of the groups. In particular, no significant cardiac lesions
were observed in either of the groups. In healthy cats, neither PIMO nor benazepril
appears to cause cardiac lesions, but future studies are needed to examine the effects of
PIMO in cats with heart disease.</p></abstract><kwd-group><kwd>angiotensin-converting-enzyme inhibitor</kwd><kwd>healthy cat</kwd><kwd>mitral valve</kwd><kwd>pimobendan</kwd></kwd-group></article-meta></front><body><p>Pimobendan (PIMO) is a benzimidazole-pyridazinone derivative that produces positive inotropic
effects by altering intracellular calcium levels and sensitizing myocardial contractions,
which causes vasodilatation by inhibiting phosphodiesterase III activity [<xref rid="r22" ref-type="bibr">22</xref>]. An important advantage of PIMO is that it increases
cardiac output without increasing myocardial oxygen demand. PIMO is used for the management of
congestive heart failure [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref>, <xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r19" ref-type="bibr">19</xref>] and for dilated
cardiomyopathy and mitral insufficiency in dogs, and it has been shown to improve clinical
signs and survival time [<xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r18" ref-type="bibr">18</xref>]. There is also some evidence that PIMO may have efficacy for managing
heart failure in cats [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r16" ref-type="bibr">16</xref>], considering that it has shown potential to improve cardiac contractility in the
presence of cardiac systolic dysfunction. Although hypertrophic cardiomyopathy is the most
common heart disease in cats and is characterized by diastolic dysfunction, some cats do
develop end-stage dilated hypertrophic cardiomyopathy, characterized by systolic myocardial
failure. In this latter setting, PIMO appears to be effective. Indeed, in one retrospective
study on cats with various heart diseases, the use of PIMO was well-tolerated [<xref rid="r13" ref-type="bibr">13</xref>], and in another study of cats with dilated
cardiomyopathy, it was shown to extend the median survival time [<xref rid="r9" ref-type="bibr">9</xref>]. In a recent study, the addition of PIMO to the standard treatment was
shown to prolong the survival time for cats with congestive heart failure caused by
hypertrophic cardiomyopathy [<xref rid="r16" ref-type="bibr">16</xref>].</p><p>Despite the benefits of treatment, adverse effects have been reported with the use of PIMO in
dogs [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r17" ref-type="bibr">17</xref>,
<xref rid="r21" ref-type="bibr">21</xref>]. In a case report of two dogs with mitral
insufficiency, a long-term administration of PIMO worsened mitral regurgitation and
ventricular hypertrophy [<xref rid="r21" ref-type="bibr">21</xref>]. Similarly, in dogs with
mild mitral insufficiency, the long-term administration of PIMO was shown to worsen mitral
regurgitation and valve lesions [<xref rid="r12" ref-type="bibr">12</xref>]. Adverse effects
on mitral valves were considered to occur because of increasing cardiac contraction, but it
was unclear whether PIMO directly affected the mitral valves. Studies in cats treated with
PIMO have not described such adverse cardiac effects [<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>], but this may be because its use in cats is less common. Therefore, the possible
adverse cardiac effects of PIMO should be investigated before its use becomes more widespread
in cats with cardiac disease.</p><p>We aimed to determine whether the long-term administration of PIMO in healthy cats produced
adverse cardiac effects, as determined by clinical and histopathological evaluation.</p><sec sec-type="materials|methods" id="s1"><title>MATERIALS AND METHODS</title><p><italic>Animals:</italic> This study was conducted in compliance with the guidelines for
the care and use of laboratory animals, and the protocol was approved by the Animal
Experimentation Committee of Nippon Veterinary and Life Science University (Approval Number
10&#x02013;83). Twelve mixed-breed male and female cats (age, 2.2 &#x000b1; 0.3 years; range, 1.7&#x02013;2.5 years;
and weight, 3.3 &#x000b1; 0.9 kg) were used. Before experimentation, all cats underwent general
clinical examination, blood and serum biochemical analyses, electrocardiography, radiography
and echocardiography. All cats were considered clinically healthy on the basis of these
examinations. Cats were housed in individual cages and fed a commercial maintenance diet
(Royal Canin male care and female care, Tokyo, Japan). Water was available <italic>ad
libitum</italic>.</p><p><italic>Study design</italic>: The study design was based on a similar study conducted in
dogs [<xref rid="r4" ref-type="bibr">4</xref>]. Twelve cats were randomly assigned into two
groups of six. One group received the angiotensin-converting-enzyme inhibitor (ACEI),
benazepril (Fortekor, Elanco Animal Health, Kobe, Japan) and was labeled the ACEI group; and
the other group received PIMO (Vetmedin, Boehringer Ingelheim Vetmedica, Inc., Tokyo, Japan)
and was labeled the PIMO group. Each group was composed of an equal number of animals of
both sexes (3 males and 3 females). Cats in the ACEI group received benazepril at a dosage
of 0.25 mg/kg q24 hr at 08:00 am for 506 days. Cats in the PIMO group received PIMO at a
dosage of 0.25 mg/kg q12 hr at 8:00 am and 8:00 pm for 506 days.</p><p>All cats underwent cardiac auscultation, heart rate measurement, echocardiography, Doppler
examination and blood pressure measurement. We also performed hematocrit measurement and
serum biochemical analyses that included total protein, albumin, blood urea nitrogen,
creatinine, sodium and potassium levels. All analyses were performed before drug
administration (day 0) and at days 16, 50, 118, 202, 320, 409 and 506 after starting drug
administration. Plasma iohexol clearance (PCio) was performed to measure the glomerular
filtration rate (GFR) on days 0, 125, 323 and 506. All examinations were performed to assess
whether cardiac pathological findings occurred in connection with hemodynamic and cardiac
structural changes. Animals were not fed for 8 hr prior to examinations, but were allowed
free access to drinking water. To allow the same investigator the time to examine all 12
cats, the examinations were performed between 2:00 pm and 6:00 pm on each assessment
day.</p><p><italic>Echocardiography and Doppler examination</italic>: Cats underwent continuous
echocardiography monitoring with an ultrasound unit (Vivid 7, GE Healthcare Japan, Tokyo,
Japan) equipped with a 3.5&#x02013;6.9 MHz transducer, without sedation or anesthesia. The same
trained investigator (Takemura) performed all examinations to exclude possible
inter-observer variability, and all measurements were obtained from three consecutive
cardiac cycles within the same time frame. The ratio of the left atrial diameter to the
aortic diameter was obtained from the right parasternal short-axis view using the B-mode
method. The thickness of the anterior and posterior mitral valve leaflet was measured using
the left apical four-chamber view, whereas end-diastolic interventricular septum thickness,
end-diastolic left-ventricular internal dimension, end-diastolic left-ventricular free-wall
thickness and fractional shortening (FS) were measured from the right parasternal short-axis
view using the M-mode method (the leading edge to leading edge method). FS was calculated
according to the following equation: FS (%)=[(diastolic left-ventricular internal
diameter-systolic left-ventricular internal diameter)/diastolic left-ventricular internal
diameter] &#x000d7;100. Any development of mitral valve or tricuspid valve regurgitation was
monitored by Doppler examination.</p><p><italic>Measurement of PCio</italic>: PCio values were measured as previously described
[<xref rid="r14" ref-type="bibr">14</xref>]. All cats were well-hydrated and had fasted
for 12 hr before measurements. Iohexol (Omnipaque 300, Daiichi Sankyo Co., Ltd., Tokyo,
Japan) was administered at a dosage of 90 mg iodine/kg via the cephalic vein (time 0), and
heparinized blood was sampled at 120, 180 and 240 min after administration. Plasma iodine
concentrations were determined by the cerium arsenate colorimetric method. The area under
the curve (AUC) was estimated from the slope (a) and intercept (A) of the elimination phase
of the curve, as determined by linear regression analysis of the final three plasma samples.
Clearance (Cl) values were calculated using the following formula: Cl
(m<italic>l</italic>/min)=dose of iohexol/AUC, where AUC=A/a. The PCio values were then
calculated as follows [<xref rid="r2" ref-type="bibr">2</xref>]: PCio
(m<italic>l</italic>/min)=(0.990778&#x000d7;Cl)&#x02212;(0.001218&#x000d7;Cl<sup>2</sup>), with the PCio values
standardized for body weight.</p><p><italic>Measurement of blood pressure</italic>: Blood pressure was measured non-invasively
by the oscillometric method using a hemomanometer (BP100D, Fukuda M-E Kogyo Co., Ltd.,
Tokyo, Japan) according to the 2007 American College of Veterinary Internal Medicine
guidelines [<xref rid="r3" ref-type="bibr">3</xref>]. Cats were individually housed in dimly
lit rooms and calmed. Blood pressure was measured repeatedly until stable values were
obtained.</p><p><italic>Necropsy examination and histopathology</italic>: All cats were euthanized by
intravenous administration of sodium pentobarbital and potassium chloride on day 507.
Histopathological examinations were performed by a veterinary pathologist (Machida) who was
blinded to the treatment groups. A complete post-mortem examination was performed on each
cat immediately after euthanasia. Tissue samples collected at necropsy were fixed in 10%
neutral buffered formalin and processed using routine methods for paraffin embedding. We
then stained 5-<italic>&#x000b5;</italic>m thick sections with hematoxylin and eosin for light
microscopy. Selected sections of cardiac tissue, including the septal and parietal valve
leaflets of the mitral valve and myocardia, were stained with Masson&#x02019;s trichrome, periodic
acid-Schiff, alcian blue (pH 2.5) and toluidine blue.</p><p><italic>Statistical analysis</italic>: Statistical analyses were performed using Dr. SPSS
II (IBM, Tokyo, Japan). Parameters were not normally distributed by Kolmogorov-Smirnov
analysis and were expressed as medians (25th and 75th percentiles). Comparison between the
baseline parameters of both groups was performed using the Mann-Whitney <italic>U</italic>
test. Changes in parameters measured after drug administration were evaluated by repeated
measures analysis of the variance with a split plot design. This test was conducted with the
observation day as the intra-subject factor and the drugs (PIMO and benazepril) and animals
as the inter-subject factors. If <italic>P</italic>&#x0003c;0.05 was found for the observation
day and drug interactions in the analysis of variance, a post-hoc multiple comparison was
conducted using the Mann&#x02013;Whitney <italic>U</italic> test with Bonferroni correction. A
<italic>P-</italic>value&#x0003c;0.05 was considered statistically significant.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><p>As shown in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Summary of characteristics at day 0 in both groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">ACEI group</th><th align="center" rowspan="1" colspan="1">PIMO group</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">3.6 (2.6, 4.2)</td><td align="center" rowspan="1" colspan="1">3.1 (2.6, 3.9)</td><td align="center" rowspan="1" colspan="1">0.937</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">1.8 (1.8, 1.8)</td><td align="center" rowspan="1" colspan="1">1.8 (1.8, 2.3)</td><td align="center" rowspan="1" colspan="1">0.937</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="center" rowspan="1" colspan="1">154 (136, 210)</td><td align="center" rowspan="1" colspan="1">166 (162, 180)</td><td align="center" rowspan="1" colspan="1">0.588</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">113 (110, 134)</td><td align="center" rowspan="1" colspan="1">139 (129, 154)</td><td align="center" rowspan="1" colspan="1">0.180</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td align="center" rowspan="1" colspan="1">67 (57, 85)</td><td align="center" rowspan="1" colspan="1">82 (75, 84)</td><td align="center" rowspan="1" colspan="1">0.380</td></tr><tr><td align="left" rowspan="1" colspan="1">ALB (g/d<italic>l</italic>)</td><td align="center" rowspan="1" colspan="1">2.1 (2.0, 2.1)</td><td align="center" rowspan="1" colspan="1">2.1 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="center" rowspan="1" colspan="1">57.0 (51.8, 69.8)</td><td align="center" rowspan="1" colspan="1">82.0 (72.5, 89.3)</td><td align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN (mg/d<italic>l</italic>)</td><td align="center" rowspan="1" colspan="1">20.6 (19.4, 22.8)</td><td align="center" rowspan="1" colspan="1">24.8 (22.5, 25.4)</td><td align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" rowspan="1" colspan="1">Cre (mg/d<italic>l</italic>)</td><td align="center" rowspan="1" colspan="1">0.9 (0.8, 1.0)</td><td align="center" rowspan="1" colspan="1">0.9 (0.9, 1.0)</td><td align="center" rowspan="1" colspan="1">0.818</td></tr><tr><td align="left" rowspan="1" colspan="1">Na (mEq/<italic>l</italic>)</td><td align="center" rowspan="1" colspan="1">156.0 (156.0, 157.5)</td><td align="center" rowspan="1" colspan="1">157.5 (157.0, 158.8)</td><td align="center" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" rowspan="1" colspan="1">K (mEq/<italic>l</italic>)</td><td align="center" rowspan="1" colspan="1">3.8 (3.6, 4.0)</td><td align="center" rowspan="1" colspan="1">3.7 (3.5, 3.8)</td><td align="center" rowspan="1" colspan="1">0.818</td></tr><tr><td align="left" rowspan="1" colspan="1">Cl (mEq/<italic>l</italic>)</td><td align="center" rowspan="1" colspan="1">122.5 (121.3, 123.8)</td><td align="center" rowspan="1" colspan="1">123.0 (122.3, 124.5)</td><td align="center" rowspan="1" colspan="1">0.589</td></tr><tr><td align="left" rowspan="1" colspan="1">PCio (m<italic>l</italic>/min/kg)</td><td align="center" rowspan="1" colspan="1">2.9 (2.7, 3.2)</td><td align="center" rowspan="1" colspan="1">2.8 (2.2, 3.9)</td><td align="center" rowspan="1" colspan="1">0.937</td></tr><tr><td align="left" rowspan="1" colspan="1">LAAo</td><td align="center" rowspan="1" colspan="1">1.4 (1.3, 1.4)</td><td align="center" rowspan="1" colspan="1">1.3 (1.2, 1.3)</td><td align="center" rowspan="1" colspan="1">0.485</td></tr><tr><td align="left" rowspan="1" colspan="1">IVSd (mm)</td><td align="center" rowspan="1" colspan="1">0.4 (0.3, 0.4)</td><td align="center" rowspan="1" colspan="1">0.3 (0.3, 0.4)</td><td align="center" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" rowspan="1" colspan="1">LVIDd (mm)</td><td align="center" rowspan="1" colspan="1">1.6 (1.5, 1.6)</td><td align="center" rowspan="1" colspan="1">1.6 (1.2, 1.7)</td><td align="center" rowspan="1" colspan="1">0.818</td></tr><tr><td align="left" rowspan="1" colspan="1">LVPWd (mm)</td><td align="center" rowspan="1" colspan="1">0.4 (0.4, 0.4)</td><td align="center" rowspan="1" colspan="1">0.3 (0.3, 0.4)</td><td align="center" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" rowspan="1" colspan="1">FS(%)</td><td align="center" rowspan="1" colspan="1">33.9 (33.2, 38.3)</td><td align="center" rowspan="1" colspan="1">37.6 (35.0, 41.0)</td><td align="center" rowspan="1" colspan="1">0.394</td></tr><tr><td align="left" rowspan="1" colspan="1">AML (mm)</td><td align="center" rowspan="1" colspan="1">0.1 (0.1, 0.1)</td><td align="center" rowspan="1" colspan="1">0.1 (0.1, 0.1)</td><td align="center" rowspan="1" colspan="1">0.394</td></tr><tr><td align="left" rowspan="1" colspan="1">PML (mm)</td><td align="center" rowspan="1" colspan="1">0.1 (0.1, 0.1)</td><td align="center" rowspan="1" colspan="1">0.1 (0.1, 0.1)</td><td align="center" rowspan="1" colspan="1">0.699</td></tr></tbody></table><table-wrap-foot><p>Values are presented as medians (25th and 75th percentile). Abbreviations: PCio,
Plasma iohexol clearance; LAAo, left atrium to aortic root ratio; IVSd, end-diastolic
interventricular septum thickness; LVIDd, end-diastolic left-ventricular internal
dimension; LVPWd, end-diastolic left-ventricular posterior wall thickness; FS,
fractional shortening; AML, anterior mitral valve leaflet; PML, posterior mitral valve
leaflet.</p></table-wrap-foot></table-wrap>, there were no significant differences in baseline parameters between the
groups (<italic>P</italic>&#x0003e;0.05). Body weight, heart rate, and systolic and diastolic
blood pressures did not show significant changes during the 506-day study period, and there
were no significant differences between the groups (<italic>P</italic>&#x02265;0.162; <xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Cardiovascular measurements by day of treatment with pimobendan or
benazepril</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="3" align="left"/><th colspan="8" align="center" rowspan="1">Day</th></tr><tr><th colspan="8" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">16</th><th align="center" rowspan="1" colspan="1">50</th><th align="center" rowspan="1" colspan="1">118</th><th align="center" rowspan="1" colspan="1">202</th><th align="center" rowspan="1" colspan="1">320</th><th align="center" rowspan="1" colspan="1">409</th><th align="center" rowspan="1" colspan="1">506</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1">Body weight (kg)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">3.7 (2.7, 4.2)</td><td align="center" rowspan="1" colspan="1">3.7 (2.7, 4.2)</td><td align="center" rowspan="1" colspan="1">3.8 (2.6, 4.2)</td><td align="center" rowspan="1" colspan="1">3.8 (2.6, 4.2)</td><td align="center" rowspan="1" colspan="1">4.2 (3.1, 4.6)</td><td align="center" rowspan="1" colspan="1">4.3 (3.2, 4.6)</td><td align="center" rowspan="1" colspan="1">4.2 (3.3, 4.3)</td><td align="center" rowspan="1" colspan="1">4.4 (3.5, 4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">3.2 (2.6, 4.0)</td><td align="center" rowspan="1" colspan="1">3.2 (2.6, 4.0)</td><td align="center" rowspan="1" colspan="1">3.2 (2.5, 4.1)</td><td align="center" rowspan="1" colspan="1">3.2 (2.5, 4.2)</td><td align="center" rowspan="1" colspan="1">3.7 (2.8, 4.7)</td><td align="center" rowspan="1" colspan="1">3.7 (3.0, 4.6)</td><td align="center" rowspan="1" colspan="1">3.8 (2.9, 4.6)</td><td align="center" rowspan="1" colspan="1">3.9 (2.9, 4.6)</td></tr><tr><td align="left" colspan="10" rowspan="1">Heart rate (bpm)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">155 (136, 211)</td><td align="center" rowspan="1" colspan="1">150 (139, 174)</td><td align="center" rowspan="1" colspan="1">161 (146, 201)</td><td align="center" rowspan="1" colspan="1">165 (139, 179)</td><td align="center" rowspan="1" colspan="1">NP</td><td align="center" rowspan="1" colspan="1">171 (153, 177)</td><td align="center" rowspan="1" colspan="1">169 (151, 191)</td><td align="center" rowspan="1" colspan="1">185 (157, 196)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">166 (163, 181)</td><td align="center" rowspan="1" colspan="1">172 (138, 188)</td><td align="center" rowspan="1" colspan="1">163 (157, 175)</td><td align="center" rowspan="1" colspan="1">170 (159, 177)</td><td align="center" rowspan="1" colspan="1">NP</td><td align="center" rowspan="1" colspan="1">172 (170, 180)</td><td align="center" rowspan="1" colspan="1">177 (160, 195)</td><td align="center" rowspan="1" colspan="1">188 (163, 200)</td></tr><tr><td align="left" colspan="2" rowspan="1">SBP (mmHg)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">113 (111, 134)</td><td align="center" rowspan="1" colspan="1">110 (106, 122)</td><td align="center" rowspan="1" colspan="1">126 (123, 137)</td><td align="center" rowspan="1" colspan="1">131 (129, 131)</td><td align="center" rowspan="1" colspan="1">NP</td><td align="center" rowspan="1" colspan="1">130 (125, 138)</td><td align="center" rowspan="1" colspan="1">138 (127, 143)</td><td align="center" rowspan="1" colspan="1">139 (135, 145)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">139 (130, 154)</td><td align="center" rowspan="1" colspan="1">133 (124, 147)</td><td align="center" rowspan="1" colspan="1">130 (126, 142)</td><td align="center" rowspan="1" colspan="1">141 (128, 147)</td><td align="center" rowspan="1" colspan="1">NP</td><td align="center" rowspan="1" colspan="1">122 (115, 147)</td><td align="center" rowspan="1" colspan="1">136 (128, 143)</td><td align="center" rowspan="1" colspan="1">141 (127, 147)</td></tr><tr><td align="left" colspan="10" rowspan="1">DBP (mmHg)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">67 (58, 85)</td><td align="center" rowspan="1" colspan="1">59 (55, 72)</td><td align="center" rowspan="1" colspan="1">66 (63, 77)</td><td align="center" rowspan="1" colspan="1">68 (65, 76)</td><td align="center" rowspan="1" colspan="1">NP</td><td align="center" rowspan="1" colspan="1">76 (62, 80)</td><td align="center" rowspan="1" colspan="1">72 (67, 79)</td><td align="center" rowspan="1" colspan="1">90 (86, 93)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">82 (75, 84)</td><td align="center" rowspan="1" colspan="1">68 (63, 79)</td><td align="center" rowspan="1" colspan="1">68 (66, 83)</td><td align="center" rowspan="1" colspan="1">79 (76, 84)</td><td align="center" rowspan="1" colspan="1">NP</td><td align="center" rowspan="1" colspan="1">87 (77, 90)</td><td align="center" rowspan="1" colspan="1">80 (77, 83)</td><td align="center" rowspan="1" colspan="1">80 (69, 95)</td></tr></tbody></table><table-wrap-foot><p>Values are presented as medians (25th and 75th percentile) for body weight, heart
rate, and systolic and diastolic blood pressure (SBP and DBP, respectively) in both
groups before (day 0) and at days 16, 50, 118, 202, 320, 409 and 506 after drug
administration. No significant differences were observed for all parameters between
two groups (<italic>P</italic>&#x02265;0.059).</p></table-wrap-foot></table-wrap>). In addition, no significant differences were observed for any parameters
between the groups during the study (<italic>P</italic>&#x02265;0.093; <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Hematocrit and biochemistry measurements by day of treatment with pimobendan or
benazepril</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="3" align="left"/><th colspan="8" align="center" rowspan="1">Day</th></tr><tr><th colspan="8" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">16</th><th align="center" rowspan="1" colspan="1">50</th><th align="center" rowspan="1" colspan="1">118</th><th align="center" rowspan="1" colspan="1">202</th><th align="center" rowspan="1" colspan="1">320</th><th align="center" rowspan="1" colspan="1">409</th><th align="center" rowspan="1" colspan="1">506</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1">Hematocrit (%)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">36 (35, 38)</td><td align="center" rowspan="1" colspan="1">34 (32, 38)</td><td align="center" rowspan="1" colspan="1">34 (33, 38)</td><td align="center" rowspan="1" colspan="1">40 (36, 42)</td><td align="center" rowspan="1" colspan="1">37 (35, 44)</td><td align="center" rowspan="1" colspan="1">38 (38, 40)</td><td align="center" rowspan="1" colspan="1">35 (32, 39)</td><td align="center" rowspan="1" colspan="1">39 (36, 42)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">38 (36, 41)</td><td align="center" rowspan="1" colspan="1">35 (34, 38)</td><td align="center" rowspan="1" colspan="1">36 (33, 40)</td><td align="center" rowspan="1" colspan="1">40 (38, 41)</td><td align="center" rowspan="1" colspan="1">37 (34, 38)</td><td align="center" rowspan="1" colspan="1">37 (32, 41)</td><td align="center" rowspan="1" colspan="1">33 (33, 39)</td><td align="center" rowspan="1" colspan="1">37 (35, 40)</td></tr><tr><td align="left" colspan="10" rowspan="1">Total protein (g/d<italic>l</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">7.0 (6.5, 7.2)</td><td align="center" rowspan="1" colspan="1">7.3 (6.8, 7.6)</td><td align="center" rowspan="1" colspan="1">7.0 (6.7, 7.3)</td><td align="center" rowspan="1" colspan="1">6.7 (6.5, 6.9)</td><td align="center" rowspan="1" colspan="1">7.4 (7, 7.4)</td><td align="center" rowspan="1" colspan="1">7.4 (7.1, 7.6)</td><td align="center" rowspan="1" colspan="1">7.0 (6.7, 7.1)</td><td align="center" rowspan="1" colspan="1">7.3 (7.1, 7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">6.8 (6.7, 6.8)</td><td align="center" rowspan="1" colspan="1">7.1 (6.8, 7.2)</td><td align="center" rowspan="1" colspan="1">7.3 (7.0, 7.3)</td><td align="center" rowspan="1" colspan="1">6.5 (6.4, 6.7)</td><td align="center" rowspan="1" colspan="1">7.2 (7.0, 7.4)</td><td align="center" rowspan="1" colspan="1">7.1 (7.0, 7.2)</td><td align="center" rowspan="1" colspan="1">6.7 (6.5, 6.8)</td><td align="center" rowspan="1" colspan="1">7.1 (6.6, 7.2)</td></tr><tr><td align="left" colspan="10" rowspan="1">Albumin (g/d<italic>l</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">2.1 (2.1, 2.1)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.0 (1.9, 2.2)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.1 (2.0, 2.1)</td><td align="center" rowspan="1" colspan="1">2.1 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.3 (2.2, 2.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">2.1 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.2 (2.2, 2.3)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.1 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.2 (2.2, 2.3)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1, 2.3)</td><td align="center" rowspan="1" colspan="1">2.2 (2.1, 2.2)</td><td align="center" rowspan="1" colspan="1">2.3 (2.3, 2.4)</td></tr><tr><td align="left" colspan="10" rowspan="1">BUN (mg/d<italic>l</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">20.6 (19.4, 22.8)</td><td align="center" rowspan="1" colspan="1">26.7 (26.0, 27.0)</td><td align="center" rowspan="1" colspan="1">26.8 (25.4, 29.3)</td><td align="center" rowspan="1" colspan="1">24.4 (23.4, 25.3)</td><td align="center" rowspan="1" colspan="1">32.1 (28.7, 32.3)</td><td align="center" rowspan="1" colspan="1">23.8 (20.8, 24.3)</td><td align="center" rowspan="1" colspan="1">23.3 (21.4, 26.5)</td><td align="center" rowspan="1" colspan="1">21.8 (21.3, 25.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">24.8 (22.5, 25.4)</td><td align="center" rowspan="1" colspan="1">28.3 (26.2, 30.7)</td><td align="center" rowspan="1" colspan="1">26.9 (26.6, 28.5)</td><td align="center" rowspan="1" colspan="1">25.5 (23.3, 28.6)</td><td align="center" rowspan="1" colspan="1">33.7 (30.9, 36.9)</td><td align="center" rowspan="1" colspan="1">26.7 (24.6, 27.9)</td><td align="center" rowspan="1" colspan="1">27.7 (24.3, 30.4)</td><td align="center" rowspan="1" colspan="1">23.9 (23.3, 24.4)</td></tr><tr><td align="left" colspan="10" rowspan="1">Creatinine (mg/d<italic>l</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">0.9 (0.8, 1.0)</td><td align="center" rowspan="1" colspan="1">0.9 (0.8, 1.0)</td><td align="center" rowspan="1" colspan="1">1.0 (0.8, 1.1)</td><td align="center" rowspan="1" colspan="1">0.8 (0.7, 0.8)</td><td align="center" rowspan="1" colspan="1">0.9 (0.7, 0.9)</td><td align="center" rowspan="1" colspan="1">1.1 (0.9, 1.1)</td><td align="center" rowspan="1" colspan="1">1.0 (0.8, 1.0)</td><td align="center" rowspan="1" colspan="1">0.9 (0.8, 0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">0.9 (0.9, 1.0)</td><td align="center" rowspan="1" colspan="1">0.9 (0.8, 0.9)</td><td align="center" rowspan="1" colspan="1">0.9 (0.8, 0.9)</td><td align="center" rowspan="1" colspan="1">0.8 (0.8, 0.9)</td><td align="center" rowspan="1" colspan="1">0.8 (0.7, 0.9)</td><td align="center" rowspan="1" colspan="1">0.9 (0.9, 1.0)</td><td align="center" rowspan="1" colspan="1">0.8 (0.7, 1.0)</td><td align="center" rowspan="1" colspan="1">0.8 (0.8, 0.9)</td></tr><tr><td align="left" colspan="10" rowspan="1">Sodium (mEq/<italic>l</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">156 (156, 158)</td><td align="center" rowspan="1" colspan="1">155 (153, 155)</td><td align="center" rowspan="1" colspan="1">156 (154, 157)</td><td align="center" rowspan="1" colspan="1">153 (152, 154)</td><td align="center" rowspan="1" colspan="1">154 (153, 155)</td><td align="center" rowspan="1" colspan="1">154 (153, 154)</td><td align="center" rowspan="1" colspan="1">152 (151, 153)</td><td align="center" rowspan="1" colspan="1">148 (147, 150)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">158 (157, 159)</td><td align="center" rowspan="1" colspan="1">155 (155, 155)</td><td align="center" rowspan="1" colspan="1">156 (155, 157)</td><td align="center" rowspan="1" colspan="1">153 (153, 154)</td><td align="center" rowspan="1" colspan="1">156 (154, 156)</td><td align="center" rowspan="1" colspan="1">156 (153, 158)</td><td align="center" rowspan="1" colspan="1">154 (153, 154)</td><td align="center" rowspan="1" colspan="1">149 (148, 151)</td></tr><tr><td align="left" colspan="10" rowspan="1">Potassium (mEq/<italic>l</italic>)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">3.8 (3.6, 4.0)</td><td align="center" rowspan="1" colspan="1">3.9 (3.7, 3.9)</td><td align="center" rowspan="1" colspan="1">3.9 (3.7, 3.9)</td><td align="center" rowspan="1" colspan="1">4.5 (4.2, 5.1)</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td><td align="center" rowspan="1" colspan="1">4.1 (4.0, 4.3)</td><td align="center" rowspan="1" colspan="1">3.8 (3.5, 3.9)</td><td align="center" rowspan="1" colspan="1">4.3 (4.2, 4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">3.7 (3.5, 3.8)</td><td align="center" rowspan="1" colspan="1">3.9 (3.7, 4.3)</td><td align="center" rowspan="1" colspan="1">4.3 (4.1, 4.6)</td><td align="center" rowspan="1" colspan="1">4.3 (4.1, 4.5)</td><td align="center" rowspan="1" colspan="1">3.8 (3.7, 3.8)</td><td align="center" rowspan="1" colspan="1">3.9 (3.6, 4.1)</td><td align="center" rowspan="1" colspan="1">3.7 (3.6, 3.8)</td><td align="center" rowspan="1" colspan="1">4.1 (4.0, 4.3)</td></tr></tbody></table><table-wrap-foot><p>Values are presented as medians (25th and 75th percentile) for hematocrit and
biochemistry measurements in both groups before (day 0) and at days 16, 50, 118, 202,
320, 409 and 506 after drug administration. No significant differences were observed
for all parameters between the two groups (<italic>P</italic>&#x02265;0.093). Abbreviations:
ACEI, angiotensin-converting enzyme inhibitor; PIMO, pimobendan.</p></table-wrap-foot></table-wrap>). Specifically, we did not detect any cardiac murmurs, and the hematocrit and
serum biochemical parameters remained unchanged and comparable between groups. However,
although PCio remained stable for both groups (<italic>P</italic>&#x02265;0.200), it was
significantly lower at day 506 than at baseline in the ACEI group
(<italic>P</italic>&#x0003c;0.05; <xref rid="tbl_004" ref-type="table">Table
4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Plasma iohexol clearance by day of treatment with pimobendan or
benazepril</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" colspan="1">PCio (m<italic>l</italic>/min/kg)</th><th colspan="4" align="center" rowspan="1">Day</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">125</th><th align="center" rowspan="1" colspan="1">323</th><th align="center" rowspan="1" colspan="1">506</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACEI group</td><td align="center" rowspan="1" colspan="1">2.9 (2.7, 3.2)</td><td align="center" rowspan="1" colspan="1">2.4 (2.2, 2.9)</td><td align="center" rowspan="1" colspan="1">2.3 (2.1, 2.9)</td><td align="center" rowspan="1" colspan="1">2.1 (2.0, 2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">PIMO group</td><td align="center" rowspan="1" colspan="1">2.8 (2.2, 3.9)</td><td align="center" rowspan="1" colspan="1">2.8 (2.4, 3.1)</td><td align="center" rowspan="1" colspan="1">2.5 (2.1, 2.8)</td><td align="center" rowspan="1" colspan="1">2.3 (2.1, 2.6)</td></tr></tbody></table><table-wrap-foot><p>Values are presented as medians (25th and 75th percentile) for plasma iohexol
clearance (PCio) values in the two groups before drug administration (day 0), and at
days 125,323 and 506 after drug administration. No significant differences were
observed for PCio value between the two groups (<italic>P</italic>&#x02265;0.200).
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; PIMO, pimobendan.</p></table-wrap-foot></table-wrap>). There were no significant changes in echocardiographic measurements during
the treatment period (<xref rid="tbl_005" ref-type="table">Table 5</xref><table-wrap id="tbl_005" orientation="portrait" position="float"><label>Table 5.</label><caption><title>Echocardiography measurements and the radiographic vertebral heart score by day
of treatment with pimobendan or benazepril</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1"/><th colspan="8" valign="top" align="center" rowspan="1">Day</th></tr><tr><th colspan="8" rowspan="1"><hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">0</th><th valign="top" align="center" rowspan="1" colspan="1">16</th><th valign="top" align="center" rowspan="1" colspan="1">50</th><th valign="top" align="center" rowspan="1" colspan="1">118</th><th valign="top" align="center" rowspan="1" colspan="1">202</th><th valign="top" align="center" rowspan="1" colspan="1">320</th><th valign="top" align="center" rowspan="1" colspan="1">409</th><th valign="top" align="center" rowspan="1" colspan="1">506</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">LAAo (cm)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">1.37 (1.34, 1.39)</td><td align="center" valign="top" rowspan="1" colspan="1">1.35 (1.28, 1.43)</td><td align="center" valign="top" rowspan="1" colspan="1">1.37 (1.24, 1.45)</td><td align="center" valign="top" rowspan="1" colspan="1">1.43 (1.27, 1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.47 (1.28, 1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.24 (1.19, 1.44)</td><td align="center" valign="top" rowspan="1" colspan="1">1.16 (1.1, 1.23)</td><td align="center" valign="top" rowspan="1" colspan="1">1.15 (1.12, 1.17)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 (1.23, 1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">1.42 (1.36, 1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.31 (1.22, 1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.21, 1.32)</td><td align="center" valign="top" rowspan="1" colspan="1">1.34 (1.11, 1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">1.37 (1.33, 1.42)</td><td align="center" valign="top" rowspan="1" colspan="1">1.37 (1.24, 1.39)</td><td align="center" valign="top" rowspan="1" colspan="1">1.15 (1.09, 1.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IVSd (cm)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">0.37 (0.34, 0.44)</td><td align="center" valign="top" rowspan="1" colspan="1">0.36 (0.34, 0.38)</td><td align="center" valign="top" rowspan="1" colspan="1">0.44 (0.39, 0.49)</td><td align="center" valign="top" rowspan="1" colspan="1">0.36 (0.34, 0.45)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.39, 0.43)</td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.38, 0.39)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.43, 0.44)</td><td align="center" valign="top" rowspan="1" colspan="1">0.41 (0.38, 0.44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">0.31 (0.3, 0.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35 (0.34, 0.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (0.38, 0.43)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 (0.3, 0.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.38 (0.33, 0.43)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35 (0.34, 0.38)</td><td align="center" valign="top" rowspan="1" colspan="1">0.44 (0.42, 0.46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.36, 0.46)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LVIDd (cm)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">1.57 (1.52, 1.58)</td><td align="center" valign="top" rowspan="1" colspan="1">1.7 (1.49, 1.84)</td><td align="center" valign="top" rowspan="1" colspan="1">1.56 (1.43, 1.76)</td><td align="center" valign="top" rowspan="1" colspan="1">1.74 (1.47, 1.75)</td><td align="center" valign="top" rowspan="1" colspan="1">1.67 (1.54, 1.79)</td><td align="center" valign="top" rowspan="1" colspan="1">1.55 (1.48, 1.66)</td><td align="center" valign="top" rowspan="1" colspan="1">1.62 (1.48, 1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1.67 (1.59, 1.74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">1.56 (1.25, 1.67)</td><td align="center" valign="top" rowspan="1" colspan="1">1.62 (1.48, 1.68)</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 (1.37, 1.68)</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 (1.35, 1.66)</td><td align="center" valign="top" rowspan="1" colspan="1">1.58 (1.5, 1.75)</td><td align="center" valign="top" rowspan="1" colspan="1">1.52 (1.33, 1.72)</td><td align="center" valign="top" rowspan="1" colspan="1">1.52 (1.44, 1.58)</td><td align="center" valign="top" rowspan="1" colspan="1">1.46 (1.32, 1.58)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LVPWd (cm)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">0.38 (0.36, 0.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 (0.33, 0.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.35, 0.42)</td><td align="center" valign="top" rowspan="1" colspan="1">0.38 (0.33, 0.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.36, 0.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.41 (0.38, 0.42)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (0.37, 0.47)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.42, 0.44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">0.35 (0.32, 0.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35 (0.32, 0.44)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.35, 0.46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 (0.33, 0.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.38 (0.37, 0.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.36, 0.42)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.39, 0.47)</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 (0.4, 0.47)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FS (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">33.9 (33.2, 38.3)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (35.4, 36.9)</td><td align="center" valign="top" rowspan="1" colspan="1">40.8 (37.9, 43.8)</td><td align="center" valign="top" rowspan="1" colspan="1">34.4 (31.3, 39)</td><td align="center" valign="top" rowspan="1" colspan="1">43.4 (39.7, 46.4)</td><td align="center" valign="top" rowspan="1" colspan="1">41.4 (36.3, 46.6)</td><td align="center" valign="top" rowspan="1" colspan="1">44.5 (39.4, 47.9)</td><td align="center" valign="top" rowspan="1" colspan="1">43.9 (42.7, 45.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">37.6 (35, 41)</td><td align="center" valign="top" rowspan="1" colspan="1">32.5 (30.4, 38.5)</td><td align="center" valign="top" rowspan="1" colspan="1">43.7 (36.1, 52.4)</td><td align="center" valign="top" rowspan="1" colspan="1">37.8 (29.3, 39.2)</td><td align="center" valign="top" rowspan="1" colspan="1">33.9 (28.9, 41.9)</td><td align="center" valign="top" rowspan="1" colspan="1">40.4 (32, 47.5)</td><td align="center" valign="top" rowspan="1" colspan="1">42.7 (38.9, 47.4)</td><td align="center" valign="top" rowspan="1" colspan="1">42.7 (35.8, 48.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AML (cm)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.09, 0.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.09 (0.08, 0.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16 (0.14, 0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.11, 0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.1, 0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.1, 0.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11 (0.1, 0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.09, 0.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">0.09 (0.08, 0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.09, 0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.1, 0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.12, 0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.12, 0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.1, 0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11 (0.08, 0.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.09, 0.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PML (cm)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACEI group</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.1, 0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.09, 0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13 (0.11, 0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.12, 0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.08, 0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.09, 0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.11, 0.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.09, 0.14)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PIMO group</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.11, 0.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (0.09, 0.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (0.1, 0.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (0.12, 0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16 (0.12, 0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11 (0.11, 0.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11 (0.1, 0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11 (0.09, 0.16)</td></tr></tbody></table><table-wrap-foot><p>Values are presented as medians (25th and 75th percentile) for echocardiography
measurements and the radiographic vertebral heart score in both groups before (day 0)
and at days 16, 50, 118, 202, 320, 409 and 506 after drug administration.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; PIMO, pimobendan; LAAo,
left atrium to aorta ratio; IVSd, end-diastolic interventricular septum thickness;
LVFWd, end-diastolic left-ventricular free-wall thickness; LVIDd, end-diastolic
left-ventricular internal dimension; FS, fractional shortening; AML, anterior mitral
valve leaflet; PML, posterior mitral valve leaflet; VHS, vertebral heart score.</p></table-wrap-foot></table-wrap>), and no significant differences were observed between the two treatment
groups (<italic>P</italic>&#x02265;0.148).</p><p>Cats from both groups had evidence of gross cardiac lesions. The septal and parietal valve
leaflets of the mitral valve were slightly thickened in three cats in the ACEI group and two
cats in the PIMO group (<xref ref-type="fig" rid="fig_001">Fig 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Macroscopic and histological findings of the mitral valves from cats administered
either pimobendan (A &#x00026; B) or benazepril (C &#x00026; D).</p></caption><graphic xlink:href="jvms-78-1099-g001"/></fig>). The thickened valves were opaque and white, but the surface was smooth and
glistening with no evidence of thrombus formation. Significant gross lesions were not
observed in other visceral organs.</p><p>All cats had mild-to-moderate histopathological changes in both mitral valve leaflets, with
the distal halves being more affected than the proximal halves. The main pathological
condition was deposition of acid mucopolysaccharides, primarily within the spongiosa layer
of the valve leaflet (<xref ref-type="fig" rid="fig_001">Fig 1</xref>). Valvular fibrosis
was also present, although it was not the predominant histological feature, and inflammatory
infiltrates were absent. Therefore, the spongiosa layer was expanded, with focal disruption
of the fibrosa by mucopolysaccharide-rich spongiosa, although there were no apparent
qualitative or quantitative differences between the groups with respect to the development
of these valvular lesions. No other valvular, vascular or myocardial lesions were detected
in either of the groups, and no histopathological changes were detected in other visceral
organs.</p></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>This study demonstrates that long-term administration of PIMO did not produce significant
pathological cardiac lesions/adverse effects in healthy cats, which suggests that PIMO might
not have the same adverse effects in cats as those reported in dogs [<xref rid="r4" ref-type="bibr">4</xref>]. However, although no other valvular, vascular or myocardial lesions
were detected, all cats did develop mild-to-moderate myxomatous mitral valve degeneration.
The lesions of the mitral valve leaflets included deposition of acid mucopolysaccharides,
primarily within the spongiosa layer of the valve leaflet, and valvular fibrosis. All cats
in both groups had these changes, and the magnitude of change was equivalent between the two
groups.</p><p>PIMO and benazepril may not affect cardiac function or hemodynamic status in cats. Indeed,
neither PIMO nor benazepril showed any tendency toward a change in echocardiography
measurements or GFR during the study, making it unlikely that these caused the myxomatous
mitral valve degeneration. In an early study of the incidence of cardiovascular disease in
cats, of the 202 cats examined at necropsy, 12 (5.9%) had mitral valve lesions (including
endocarditis, fibrosis and stenosis) and 17 (8.4%) had myocardial lesions (including
hypertrophy, hemorrhage, infarct and fibrosis) [<xref rid="r20" ref-type="bibr">20</xref>].
In our cats, the prevalence of mitral valve degeneration was much higher, but no cat had
clinical evidence of mitral regurgitation during the study period. These pathological mitral
valve changes were only slight compared with the degree of myxomatous mitral valve
degeneration previously observed in dogs. Because no studies have been reported on the
development of mitral valve changes with age in healthy cats, it is unclear whether the
myxomatous mitral valve degeneration seen in our cats occurred spontaneously, as a natural
consequence of aging. A further study is needed to clarify this point.</p><p>Cardiomyopathy is the most common cardiac disease in cats. In our study, myocardial lesions
were not detected in cats treated with either benazepril or PIMO. In a previous case report
of two dogs treated with PIMO, the authors reported that myocardial hypertrophy occurred
during treatment of both dogs [<xref rid="r21" ref-type="bibr">21</xref>]. However, these
dogs were treated with PIMO without any prior echocardiographic examination. Excluding this
case report, no adverse effect has been demonstrated conclusively on the myocardia following
treatment with PIMO in cats, dogs or humans.</p><p>The adverse effect of PIMO on mitral valves in dogs may be caused by increased cardiac
contraction, although a direct effect on the valves cannot be excluded. This effect has not
been reported in humans, suggesting that there may be species specificity in the
pharmacological action of PIMO. It has been reported that, even with the same dose of PIMO
administered to cats and dogs, the plasma elimination half-life (1.3 &#x000b1; 0.2 hr and 0.5 hr,
respectively) and Cmax (34.5 &#x000b1; 6.59 <italic>n</italic>g/m<italic>l</italic> and 3.09 &#x000b1; 0.76
<italic>n</italic>g/m<italic>l</italic>, respectively) differed considerably [<xref rid="r10" ref-type="bibr">10</xref>]. In addition, the elimination half-life and effect on
cardiac contractility of PIMO are simply not associated in dogs [<xref rid="r22" ref-type="bibr">22</xref>]. Thus, the tissue concentration and hemodynamic effects of PIMO might
be different in cats. In cats with hypertrophic cardiomyopathy, it has been shown that the
addition of PIMO to the standard treatment for congestive heart failure can prolong survival
times [<xref rid="r16" ref-type="bibr">16</xref>]. These cats received a median dose of 0.49
mg/kg/day (25th to 75th percentile, 0.40&#x02013;0.67 mg/kg/day) of PIMO. The dosage used in our
study, which was 0.25 mg/kg twice daily, could therefore be considered sufficient for
clinical efficacy in improving cardiac function in cats. However, there was no difference in
cardiac changes between the cats administered PIMO (0.25 mg/kg twice daily) and benazepril.
It is unlikely that PIMO at 0.25 mg/kg twice daily has a direct cardiac effect in healthy
cats. The present study has shown only that PIMO with clinically effective dose for cats may
not have cardiac adverse effect on cats. Extra-cardiac adverse effects of PIMO in cats
include salivation, vomiting, agitation, anorexia and constipation [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r13" ref-type="bibr">13</xref>]. However, no such adverse effects were evident in any cat in this
study.</p><p>In this study, there were no significant changes in heart rate, blood pressure or GFR after
administration of PIMO, suggesting that PIMO does not influence the hemodynamics of healthy
cats. In dogs with experimental mitral insufficiency, Kanno <italic>et al</italic>. reported
that PIMO significantly increased renal blood flow, but not GFR [<xref rid="r11" ref-type="bibr">11</xref>]. Furthermore, research has shown that PIMO did not alter renal
function in healthy dogs [<xref rid="r6" ref-type="bibr">6</xref>] and that GFR in dogs
receiving PIMO was not significantly different from GFR in dogs receiving benazepril [<xref rid="r4" ref-type="bibr">4</xref>]. Unfortunately, renal blood flow was not directly
measured in our study.</p><p>Our study had some limitations. First, because the optimal dose of PIMO is unknown for
cats, we used the same dose of PIMO as that used to treat dogs. In all prior studies into
the use of PIMO in cats, the dosage used was 0.25 mg/kg q12 hr [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r13" ref-type="bibr">13</xref>]. Given that the plasma elimination half-life and Cmax differ
considerably between cats and dogs [<xref rid="r10" ref-type="bibr">10</xref>], the required
dose and frequency of administration of PIMO in cats may differ from those in dogs. Despite
all previous studies on PIMO for cats selected the dosage based on that previously used
dosages for dogs [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r16" ref-type="bibr">16</xref>], no clinical adverse effects were reported. In addition, one study showed that
using the same dose of PIMO in cats as in dogs prolonged the survival time in cats with
hypertrophic cardiomyopathy [<xref rid="r16" ref-type="bibr">16</xref>]. These results
suggest that the use of PIMO in cats at the same dosage as that used in dogs does not
produce a clinical disadvantage. A second limitation is that cardiac contraction was
evaluated using only FS. Other methods&#x02014;such as the ejection fraction&#x02014;may be required to
observe the true effect of PIMO on cardiac contraction. In addition, PIMO has been shown to
accelerate left-ventricular isovolumetric relaxation and to improve distensibility in
conscious dogs with tachycardia-induced heart failure [<xref rid="r1" ref-type="bibr">1</xref>]. In our study, evaluation of cardiac relaxation, including the E/A ratio and
isovolumetric relaxation time, was not performed. Thus, the cardiac effects of PIMO on
echocardiography might not have been accurately assessed. A third limitation is that only
healthy cats were used, which contrasts with a prior study in dogs [<xref rid="r4" ref-type="bibr">4</xref>]. However, no study has evaluated the adverse effects of PIMO on the
mitral valves of healthy dogs. Mitral regurgitation in cats is often caused by systolic
anterior motion associated with cardiomyopathy. A further study is justified to evaluate the
possible effects of PIMO on mitral regurgitation in cats with cardiomyopathy.</p><p>In conclusion, neither PIMO nor benazepril administration was associated with cardiac
lesions in healthy cats, suggesting that both agents can be used in cats without the risk of
cardiotoxicity. However, future studies are needed to examine the adverse cardiac effects of
PIMO in cats with pre-existing heart disease. In addition, there is a need to examine
age-related alterations in the hearts of healthy cats.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Asanoi</surname><given-names>H.</given-names></name><name><surname>Ishizaka</surname><given-names>S.</given-names></name><name><surname>Kameyama</surname><given-names>T.</given-names></name><name><surname>Ishise</surname><given-names>H.</given-names></name><name><surname>Sasayama</surname><given-names>S.</given-names></name></person-group><year>1994</year>. <article-title>Disparate inotropic and lusitropic
responses to pimobendan in conscious dogs with tachycardia-induced heart
failure</article-title>. <source><italic>J. Cardiovasc.
Pharmacol.</italic></source><volume>23</volume>: <fpage>268</fpage>&#x02013;<lpage>274</lpage>.
doi: <pub-id pub-id-type="doi">10.1097/00005344-199402000-00014</pub-id><pub-id pub-id-type="pmid">7511757</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Br&#x000f6;chner-Mortensen</surname><given-names>J.</given-names></name></person-group><year>1972</year>. <article-title>A simple method for the determination of
glomerular filtration rate</article-title>. <source><italic>Scand. J. Clin. Lab.
Invest.</italic></source><volume>30</volume>: <fpage>271</fpage>&#x02013;<lpage>274</lpage>.
doi: <pub-id pub-id-type="doi">10.3109/00365517209084290</pub-id><pub-id pub-id-type="pmid">4629674</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Brown</surname><given-names>S.</given-names></name><name><surname>Atkins</surname><given-names>C.</given-names></name><name><surname>Bagley</surname><given-names>R.</given-names></name><name><surname>Carr</surname><given-names>A.</given-names></name><name><surname>Cowgill</surname><given-names>L.</given-names></name><name><surname>Davidson</surname><given-names>M.</given-names></name><name><surname>Egner</surname><given-names>B.</given-names></name><name><surname>Elliott</surname><given-names>J.</given-names></name><name><surname>Henik</surname><given-names>R.</given-names></name><name><surname>Labato</surname><given-names>M.</given-names></name><name><surname>Littman</surname><given-names>M.</given-names></name><name><surname>Polzin</surname><given-names>D.</given-names></name><name><surname>Ross</surname><given-names>L.</given-names></name><name><surname>Snyder</surname><given-names>P.</given-names></name><name><surname>Stepien</surname><given-names>R.</given-names></name></person-group>, American College of Veterinary Internal Medicine<year>2007</year>.
<article-title>Guidelines for the identification, evaluation, and management of systemic
hypertension in dogs and cats</article-title>. <source><italic>J. Vet. Intern.
Med.</italic></source><volume>21</volume>: <fpage>542</fpage>&#x02013;<lpage>558</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/j.1939-1676.2007.tb03005.x</pub-id><pub-id pub-id-type="pmid">17552466</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Chetboul</surname><given-names>V.</given-names></name><name><surname>Lefebvre</surname><given-names>H. P.</given-names></name><name><surname>Sampedrano</surname><given-names>C. C.</given-names></name><name><surname>Gouni</surname><given-names>V.</given-names></name><name><surname>Saponaro</surname><given-names>V.</given-names></name><name><surname>Serres</surname><given-names>F.</given-names></name><name><surname>Concordet</surname><given-names>D.</given-names></name><name><surname>Nicolle</surname><given-names>A. P.</given-names></name><name><surname>Pouchelon</surname><given-names>J. L.</given-names></name></person-group><year>2007</year>. <article-title>Comparative adverse cardiac effects of
pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve
disease: a prospective, controlled, blinded, and randomized study</article-title>.
<source><italic>J. Vet. Intern. Med.</italic></source><volume>21</volume>:
<fpage>742</fpage>&#x02013;<lpage>753</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2007.tb03016.x</pub-id><pub-id pub-id-type="pmid">17708394</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Fuentes</surname><given-names>V. L.</given-names></name><name><surname>Corcoran</surname><given-names>B.</given-names></name><name><surname>French</surname><given-names>A.</given-names></name><name><surname>Schober</surname><given-names>K. E.</given-names></name><name><surname>Kleemann</surname><given-names>R.</given-names></name><name><surname>Justus</surname><given-names>C.</given-names></name></person-group><year>2002</year>. <article-title>A double-blind, randomized,
placebo-controlled study of pimobendan in dogs with dilated
cardiomyopathy</article-title>. <source><italic>J. Vet. Intern.
Med.</italic></source><volume>16</volume>: <fpage>255</fpage>&#x02013;<lpage>261</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/j.1939-1676.2002.tb02366.x</pub-id><pub-id pub-id-type="pmid">12041654</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Fusellier</surname><given-names>M.</given-names></name><name><surname>Desfontis</surname><given-names>J. C.</given-names></name><name><surname>Le Roux</surname><given-names>A.</given-names></name><name><surname>Madec</surname><given-names>S.</given-names></name><name><surname>Gautier</surname><given-names>F.</given-names></name><name><surname>Thuleau</surname><given-names>A.</given-names></name><name><surname>Gogny</surname><given-names>M.</given-names></name></person-group><year>2008</year>. <article-title>Effect of short-term treatment with
meloxicam and pimobendan on the renal function in healthy beagle dogs</article-title>.
<source><italic>J. Vet. Pharmacol. Ther.</italic></source><volume>31</volume>:
<fpage>150</fpage>&#x02013;<lpage>155</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2885.2007.00934.x</pub-id><pub-id pub-id-type="pmid">18307507</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Gordon</surname><given-names>S. G.</given-names></name><name><surname>Saunders</surname><given-names>A. B.</given-names></name><name><surname>Roland</surname><given-names>R. M.</given-names></name><name><surname>Winter</surname><given-names>R. L.</given-names></name><name><surname>Drourr</surname><given-names>L.</given-names></name><name><surname>Achen</surname><given-names>S. E.</given-names></name><name><surname>Hariu</surname><given-names>C. D.</given-names></name><name><surname>Fries</surname><given-names>R. C.</given-names></name><name><surname>Boggess</surname><given-names>M. M.</given-names></name><name><surname>Miller</surname><given-names>M. W.</given-names></name></person-group><year>2012</year>. <article-title>Effect of oral administration of
pimobendan in cats with heart failure</article-title>. <source><italic>J. Am. Vet. Med.
Assoc.</italic></source><volume>241</volume>: <fpage>89</fpage>&#x02013;<lpage>94</lpage>.
doi: <pub-id pub-id-type="doi">10.2460/javma.241.1.89</pub-id><pub-id pub-id-type="pmid">22720992</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>H&#x000e4;ggstr&#x000f6;m</surname><given-names>J.</given-names></name><name><surname>Boswood</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>M.</given-names></name><name><surname>J&#x000f6;ns</surname><given-names>O.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Swift</surname><given-names>S.</given-names></name><name><surname>Borgarelli</surname><given-names>M.</given-names></name><name><surname>Gavaghan</surname><given-names>B.</given-names></name><name><surname>Kresken</surname><given-names>J. G.</given-names></name><name><surname>Patteson</surname><given-names>M.</given-names></name><name><surname>Ablad</surname><given-names>B.</given-names></name><name><surname>Bussadori</surname><given-names>C. M.</given-names></name><name><surname>Glaus</surname><given-names>T.</given-names></name><name><surname>Kovacevi&#x00107;</surname><given-names>A.</given-names></name><name><surname>Rapp</surname><given-names>M.</given-names></name><name><surname>Santilli</surname><given-names>R. A.</given-names></name><name><surname>Tidholm</surname><given-names>A.</given-names></name><name><surname>Eriksson</surname><given-names>A.</given-names></name><name><surname>Belanger</surname><given-names>M. C.</given-names></name><name><surname>Deinert</surname><given-names>M.</given-names></name><name><surname>Little</surname><given-names>C. J.</given-names></name><name><surname>Kvart</surname><given-names>C.</given-names></name><name><surname>French</surname><given-names>A.</given-names></name><name><surname>R&#x000f8;nn-Landbo</surname><given-names>M.</given-names></name><name><surname>Wess</surname><given-names>G.</given-names></name><name><surname>Eggertsdottir</surname><given-names>A. V.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>M. L.</given-names></name><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Lombard</surname><given-names>C. W.</given-names></name><name><surname>Dukes-McEwan</surname><given-names>J.</given-names></name><name><surname>Willis</surname><given-names>R.</given-names></name><name><surname>Louvet</surname><given-names>A.</given-names></name><name><surname>DiFruscia</surname><given-names>R.</given-names></name></person-group><year>2008</year>. <article-title>Effect of pimobendan or benazepril
hydrochloride on survival times in dogs with congestive heart failure caused by
naturally occurring myxomatous mitral valve disease: the QUEST study</article-title>.
<source><italic>J. Vet. Intern. Med.</italic></source><volume>22</volume>:
<fpage>1124</fpage>&#x02013;<lpage>1135</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2008.0150.x</pub-id><pub-id pub-id-type="pmid">18638016</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Hambrook</surname><given-names>L. E.</given-names></name><name><surname>Bennett</surname><given-names>P. F.</given-names></name></person-group><year>2012</year>. <article-title>Effect of pimobendan on the clinical
outcome and survival of cats with non-taurine responsive dilated
cardiomyopathy</article-title>. <source><italic>J. Feline Med.
Surg.</italic></source><volume>14</volume>: <fpage>233</fpage>&#x02013;<lpage>239</lpage>. doi:
<pub-id pub-id-type="doi">10.1177/1098612X11429645</pub-id><pub-id pub-id-type="pmid">22412159</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Hanzlicek</surname><given-names>A. S.</given-names></name><name><surname>Gehring</surname><given-names>R.</given-names></name><name><surname>Kukanich</surname><given-names>B.</given-names></name><name><surname>Kukanich</surname><given-names>K. S.</given-names></name><name><surname>Borgarelli</surname><given-names>M.</given-names></name><name><surname>Smee</surname><given-names>N.</given-names></name><name><surname>Olson</surname><given-names>E. E.</given-names></name><name><surname>Margiocco</surname><given-names>M.</given-names></name></person-group><year>2012</year>. <article-title>Pharmacokinetics of oral pimobendan in
healthy cats</article-title>. <source><italic>J. Vet.
Cardiol.</italic></source><volume>14</volume>: <fpage>489</fpage>&#x02013;<lpage>496</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.jvc.2012.06.002</pub-id><pub-id pub-id-type="pmid">23116650</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Kanno</surname><given-names>N.</given-names></name><name><surname>Kuse</surname><given-names>H.</given-names></name><name><surname>Kawasaki</surname><given-names>M.</given-names></name><name><surname>Hara</surname><given-names>A.</given-names></name><name><surname>Kano</surname><given-names>R.</given-names></name><name><surname>Sasaki</surname><given-names>Y.</given-names></name></person-group><year>2007</year>. <article-title>Effects of pimobendan for mitral valve
regurgitation in dogs</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>69</volume>: <fpage>373</fpage>&#x02013;<lpage>377</lpage>. doi:
<pub-id pub-id-type="doi">10.1292/jvms.69.373</pub-id><pub-id pub-id-type="pmid">17485924</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Lombard</surname><given-names>C. W.</given-names></name><name><surname>J&#x000f6;ns</surname><given-names>O.</given-names></name><name><surname>Bussadori</surname><given-names>C. M.</given-names></name></person-group><year>2006</year>. <article-title>Clinical efficacy of pimobendan versus
benazepril for the treatment of acquired atrioventricular valvular disease in
dogs</article-title>. <source><italic>J. Am. Anim. Hosp.
Assoc.</italic></source><volume>42</volume>: <fpage>249</fpage>&#x02013;<lpage>261</lpage>. doi:
<pub-id pub-id-type="doi">10.5326/0420249</pub-id><pub-id pub-id-type="pmid">16822763</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Macgregor</surname><given-names>J. M.</given-names></name><name><surname>Rush</surname><given-names>J. E.</given-names></name><name><surname>Laste</surname><given-names>N. J.</given-names></name><name><surname>Malakoff</surname><given-names>R. L.</given-names></name><name><surname>Cunningham</surname><given-names>S. M.</given-names></name><name><surname>Aronow</surname><given-names>N.</given-names></name><name><surname>Hall</surname><given-names>D. J.</given-names></name><name><surname>Williams</surname><given-names>J.</given-names></name><name><surname>Price</surname><given-names>L. L.</given-names></name></person-group><year>2011</year>. <article-title>Use of pimobendan in 170 cats
(2006-2010)</article-title>. <source><italic>J. Vet.
Cardiol.</italic></source><volume>13</volume>: <fpage>251</fpage>&#x02013;<lpage>260</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.jvc.2011.08.001</pub-id><pub-id pub-id-type="pmid">22030289</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Miyagawa</surname><given-names>Y.</given-names></name><name><surname>Takemura</surname><given-names>N.</given-names></name><name><surname>Hirose</surname><given-names>H.</given-names></name></person-group><year>2010</year>. <article-title>Evaluation of a single sampling method
for estimation of plasma iohexol clearance in dogs and cats with various kidney
functions</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>72</volume>: <fpage>271</fpage>&#x02013;<lpage>278</lpage>. doi:
<pub-id pub-id-type="doi">10.1292/jvms.09-0294</pub-id><pub-id pub-id-type="pmid">19952516</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>O&#x02019;Grady</surname><given-names>M. R.</given-names></name><name><surname>Minors</surname><given-names>S. L.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>M. L.</given-names></name><name><surname>Horne</surname><given-names>R.</given-names></name></person-group><year>2008</year>. <article-title>Effect of pimobendan on case fatality
rate in Doberman Pinschers with congestive heart failure caused by dilated
cardiomyopathy</article-title>. <source><italic>J. Vet. Intern.
Med.</italic></source><volume>22</volume>: <fpage>897</fpage>&#x02013;<lpage>904</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/j.1939-1676.2008.0116.x</pub-id><pub-id pub-id-type="pmid">18537880</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Reina-Doreste</surname><given-names>Y.</given-names></name><name><surname>Stern</surname><given-names>J. A.</given-names></name><name><surname>Keene</surname><given-names>B. W.</given-names></name><name><surname>Tou</surname><given-names>S. P.</given-names></name><name><surname>Atkins</surname><given-names>C. E.</given-names></name><name><surname>DeFrancesco</surname><given-names>T. C.</given-names></name><name><surname>Ames</surname><given-names>M. K.</given-names></name><name><surname>Hodge</surname><given-names>T. E.</given-names></name><name><surname>Meurs</surname><given-names>K. M.</given-names></name></person-group><year>2014</year>. <article-title>Case-control study of the effects of
pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive
heart failure</article-title>. <source><italic>J. Am. Vet. Med.
Assoc.</italic></source><volume>245</volume>: <fpage>534</fpage>&#x02013;<lpage>539</lpage>.
doi: <pub-id pub-id-type="doi">10.2460/javma.245.5.534</pub-id><pub-id pub-id-type="pmid">25148095</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Reinker</surname><given-names>L. N.</given-names></name><name><surname>Lee</surname><given-names>J. A.</given-names></name><name><surname>Hovda</surname><given-names>L. R.</given-names></name><name><surname>Rishniw</surname><given-names>M.</given-names></name></person-group><year>2012</year>. <article-title>Clinical signs of cardiovascular effects
secondary to suspected pimobendan toxicosis in five dogs</article-title>.
<source><italic>J. Am. Anim. Hosp. Assoc.</italic></source><volume>48</volume>:
<fpage>250</fpage>&#x02013;<lpage>255</lpage>. doi: <pub-id pub-id-type="doi">10.5326/JAAHA-MS-5775</pub-id><pub-id pub-id-type="pmid">22611208</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Summerfield</surname><given-names>N. J.</given-names></name><name><surname>Boswood</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>M. R.</given-names></name><name><surname>Gordon</surname><given-names>S. G.</given-names></name><name><surname>Dukes-McEwan</surname><given-names>J.</given-names></name><name><surname>Oyama</surname><given-names>M. A.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Patteson</surname><given-names>M.</given-names></name><name><surname>French</surname><given-names>A. T.</given-names></name><name><surname>Culshaw</surname><given-names>G. J.</given-names></name><name><surname>Braz-Ruivo</surname><given-names>L.</given-names></name><name><surname>Estrada</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>M. L.</given-names></name><name><surname>Loureiro</surname><given-names>J.</given-names></name><name><surname>Willis</surname><given-names>R.</given-names></name><name><surname>Watson</surname><given-names>P.</given-names></name></person-group><year>2012</year>. <article-title>Efficacy of pimobendan in the prevention
of congestive heart failure or sudden death in Doberman Pinschers with preclinical
dilated cardiomyopathy (the PROTECT Study)</article-title>. <source><italic>J. Vet.
Intern. Med.</italic></source><volume>26</volume>:
<fpage>1337</fpage>&#x02013;<lpage>1349</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2012.01026.x</pub-id><pub-id pub-id-type="pmid">23078651</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Fukushima</surname><given-names>R.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Hamabe</surname><given-names>L.</given-names></name><name><surname>Aytemiz</surname><given-names>D.</given-names></name><name><surname>Huai-Che</surname><given-names>H.</given-names></name><name><surname>Nakao</surname><given-names>S.</given-names></name><name><surname>Machida</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>R.</given-names></name></person-group><year>2011</year>. <article-title>The effect of pimobendan on left atrial
pressure in dogs with mitral valve regurgitation</article-title>. <source><italic>J.
Vet. Intern. Med.</italic></source><volume>25</volume>:
<fpage>1328</fpage>&#x02013;<lpage>1333</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2011.00800.x</pub-id><pub-id pub-id-type="pmid">22092624</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Tashjian</surname><given-names>R. J.</given-names></name><name><surname>Das</surname><given-names>K. M.</given-names></name><name><surname>Palich</surname><given-names>W. E.</given-names></name><name><surname>Hamlin</surname><given-names>R. L.</given-names></name><name><surname>Yarns</surname><given-names>D. A.</given-names></name></person-group><year>1965</year>. <article-title>Studies on cardiovascular disease in the
cat</article-title>. <source><italic>Ann. N. Y. Acad.
Sci.</italic></source><volume>127</volume>: <fpage>581</fpage>&#x02013;<lpage>605</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1965.tb49425.x</pub-id><pub-id pub-id-type="pmid">5217281</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Tissier</surname><given-names>R.</given-names></name><name><surname>Chetboul</surname><given-names>V.</given-names></name><name><surname>Moraillon</surname><given-names>R.</given-names></name><name><surname>Nicolle</surname><given-names>A.</given-names></name><name><surname>Carlos</surname><given-names>C.</given-names></name><name><surname>Enriquez</surname><given-names>B.</given-names></name><name><surname>Pouchelon</surname><given-names>J. L.</given-names></name></person-group><year>2005</year>. <article-title>Increased mitral valve regurgitation and
myocardial hypertrophy in two dogs with long-term pimobendan therapy</article-title>.
<source><italic>Cardiovasc. Toxicol.</italic></source><volume>5</volume>:
<fpage>43</fpage>&#x02013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1385/CT:5:1:043</pub-id><pub-id pub-id-type="pmid">15738584</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>van Meel</surname><given-names>J. C.</given-names></name><name><surname>Diederen</surname><given-names>W.</given-names></name></person-group><year>1989</year>. <article-title>Hemodynamic profile of the cardiotonic
agent pimobendan</article-title>. <source><italic>J. Cardiovasc.
Pharmacol.</italic></source><volume>14</volume><issue>Suppl 2</issue>:
<fpage>S1</fpage>&#x02013;<lpage>S6</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00005344-198900142-00002</pub-id><pub-id pub-id-type="pmid">2478784</pub-id></mixed-citation></ref></ref-list></back></article>